Navigation Links
Titan Reports Fourth Quarter 2010 Fanapt® Royalty
Date:2/3/2011

SAN FRANCISCO, Feb. 3, 2011 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (OTC Bulletin Board: TTNP) today reported that the company expects to receive a royalty payment of approximately $409,000 on fourth quarter 2010 net sales of Fanapt (iloperidone) of approximately $5.1 million. Prescriptions for Fanapt continued a steady growth trend during the fourth quarter according to analyst reports which showed that the fourth quarter 2010 average weekly prescriptions increased to 1,876 from the third quarter 2010 average weekly prescriptions of 1,449.

About Titan Pharmaceuticals

For information concerning Titan Pharmaceuticals, Inc., please visit the Company's website at www.titanpharm.com.

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.


'/>"/>
SOURCE Titan Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Titan Pharmaceuticals Announces Second Quarter 2010 Financial Results
2. Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting
3. Ascension Orthopedics Receives FDA Approval for TITAN™ Modular Total Shoulder System
4. Ascension Orthopedics Announces First Implantations of TITAN™ Modular Shoulder
5. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
6. Ascension Orthopedics Announces Implantation of the TITAN™ Modular Total Shoulder
7. Ascension Orthopedics Implants PyroTITAN™ in France
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014  BioPontis Alliance for Rare ... philanthropies, announced today the creation of a joint ... of the rare disease known as Charcot- Marie-Tooth ... alliance model earlier this month. Today,s partnership announcement ... collaborative model where researchers and all CMT dedicated ...
(Date:10/18/2014)... WASHINGTON , Oct. 18, 2014  In ... Human Rights Campaign (HRC), the nation,s largest lesbian, ... explicitly endorsed the use of Truvada for Pre-Exposure ... health tool used to prevent the spread of ... is the only brand name anti-HIV drug combination ...
(Date:10/17/2014)... UBM Medica US announces that Neurology Times ... for neurologists and other healthcare providers, features special coverage on ... discussions of the latest developments in approaches to diagnosis. ... , more than the total of those who have multiple ... can be difficult because there are no confirmatory medical tests. ...
Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... of Up to Four Years of Treatment Presented ... Schering-Plough,Corporation (NYSE: SGP ) today reported ... receptor antagonist, demonstrated,sustained viral suppression and increased CD4 ... four years of therapy in treatment-experienced,HIV-infected patients. Vicriviroc ...
... 26 Paratek Pharmaceuticals, Inc. today,announced positive Phase ... a first-in-class aminomethylcycline (AMC). The Phase 2 study ... forms of PTK 0796 to,Zyvox(R) in the treatment ... (cSSSIs). Paratek,s trial met its primary safety and,tolerability ...
Cached Medicine Technology:Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 2Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 3Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 4Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 5Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 6Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:10/20/2014)... 2014 JZ Fitness, an independently operated ... wellness programming, authorship, international lecturing and community wellness, created ... the release of the JZ Fitness nutrition app, available ... coaching thousands of individuals on nutrition, Jenn Zerling (“JZ”) ... not require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... 20, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Sit and Slim II . ... to purchase or use Sit and Slim II because it ... is promoted as weight loss product on various websites and ... market in 2010 for safety reasons, can significantly increase blood ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked ... the Every Body Walk! campaign by Kaiser Permanente. ... encourages workers to be more active outside of the workplace. ... at the end of September, was a friendly competition between ... Participating companies gave their staff pedometers and each day, ...
(Date:10/20/2014)... 2014 Final Cut Pro X Plugin developers ... Citrus theme for FCPX filmmakers . , “Fun, cool, ... the Citrus theme” Says Christina Austin, CEO of Pixel Film ... professional.” , Citrus comes with all the tools needed for ... four transitions for added style, a title screen for an ...
(Date:10/20/2014)... Punzoné , the first line of ... a lot to celebrate this month. October marks Italian Heritage ... and contributions of Americans of Italian heritage and Italians in ... it shares its favorite Italian cocktails and encourages everyone to ... even if it is only in a glass. , ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4
... -- A fetus is sensitive to, and can be affected ... University of California, Irvine, researchers recruited pregnant women and ... The women,s babies were tested after birth to assess how ... state appeared to be important to a baby,s well-being. Development ...
... , THURSDAY, Nov. 17 (HealthDay News) -- ... severe mood dysregulation spend less time looking at the ... children without the psychiatric disorders, researchers say. This ... bipolar disorder and severe mood dysregulation have difficulty determining ...
... who identify themselves as such in the workplace are ... their job than transsexuals who do not, according to ... University. "Trans-parency in the Workplace: How the ... in an upcoming issue of the Journal of ...
... that has set standards for teaching women and clinicians ... around the country to detect lumps earlier and save ... of early detection of cancer. The Center for Disease ... cancer is the most common cancer among American females. ...
... 2011 InDevR, a Boulder-based biotechnology company that ... analysis of viruses and other microorganisms, announced today ... ampliPHOX, a colorimetric detection system that incorporates core ... Transfer Office, will enhance laboratories around the world ...
... 17 (HealthDay News) -- Young athletes who routinely take hits ... they do not suffer a concussion, according to the results ... of Rochester Medical Center (URMC) said their findings could be ... mild head injuries among young people whose brains are still ...
Cached Medicine News:Health News:Mom-to-Be's Mental State May Affect Child's Development 2Health News:Bipolar Kids May Focus on Different Facial Features 2Health News:'Trans-parency' in the workplace 2Health News:Indevr launches breakthrough colorimetric detection for microarrays using core technology from CU 2Health News:Routine Head Hits in Sports May Injure Brain, Experts Warn 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: